We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




R&D Systems to Develop Cytokine Assays for Beckman

By HospiMedica staff writers
Posted on 22 Oct 2003
A nonexclusive, multi-year agreement has been announced by Beckman Coulter (Fullerton, CA, USA) and R&D Systems (Minneapolis, MN, USA) under which R&D Systems will develop automated cytokine assays and manufacture assay components designed for Beckman's Access family of immunoassay systems.

R&D Systems will develop and manufacture immunoassays based on Beckman Coulter's magnetic particle, chemiluminescent immunoassay technology. More...
The initial focus of the agreement will serve to expand Beckman's leadership position in anemia testing to include erythropoietin, a principal cytokine factor regulating red blood cell production, and soluble transferring receptor (STFR), considered the best indicator of iron deficiency.

Beckman Coulter currently offers a wide array of tests for the diagnosis and monitoring of anemia that are run on its hematology analyzers. The addition of new assays for biologics and cytokines will enhance the company's portfolio of products.

"Because we maintain a best-of-breed philosophy around our assay design, development, and manufacture, R&D Systems was clearly an excellent partner,” said Michael Whelan, vice president, immunoassay and nucleic acid testing, for Beckman Coulter. "Their expertise will be instrumental in our efforts to strengthen our position in the automated immunoassay market.”





Related Links:
Beckman Coulter
R&D Systems

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.